Definium Therapeutics (DFTX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.37

Estimate

-$0.56

Surprise

+34.0%

Score today

5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Definium Therapeutics (DFTX) reported a narrower loss than forecast — adjusted EPS of -$0.37 against the -$0.56 estimate (a 34.0% beat on a still-unprofitable quarter).

• RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $70 — benzinga, 2026-11-10
• RBC Raises Price Target on Definium Therapeutics to $70 From $66 — fiscal.ai, 2026-11-10
• Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights — fiscal.ai, 2026-11-09

TrendMatrix currently rates DFTX Sell at 5.4/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +34.0% surprise compares with a -43.6% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$33.91

Price target

$65.50

Stop

$31.54

Upside to target

+93.2%

Reward-to-risk

7.2:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$4.76B

P/E (fwd)

-18.2

52-week range

$10.46–$49.70

Off 52-week high

31.8%

RSI (14)

46

Volume vs avg

0.26×

Score today

5.4/10